Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients

21 Oct 2021

Abstract excerpt

Cancer is the leading cause of death in the geriatric dog population. Currently, the use of immune checkpoint inhibitors (ICIs) such as anti-CTLA4 antibodies has markedly improved the prognosis of several cancers in their advanced stages. However, ICIs targeting CTLA4 blockade to treat canine cancer patients are yet to define. In this study, we sought to develop, characterize and assess whether chimeric heavy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy and Immune Responses
Share to Monoclonal and Polyclonal Antibodies Research
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34675296
DOI: 10.1038/s41598-021-00325-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patientsPMID 34675296Read ↗

Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patientsSemantic proximity Read ↗

Barking Up the Right Tree: Immune Checkpoint Signatures of Human and Dog CancersSemantic proximity Read ↗

Optimizing canine T cell activation, expansion, and transductionSemantic proximity Read ↗

Nanobody-based CAR-T cells for cancer immunotherapySemantic proximity Read ↗

CAR T-Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds against Hematological MalignanciesSemantic proximity Read ↗

The Application of Nanobody in CAR-T TherapySemantic proximity Read ↗

Tasmanian devil CD28 and CTLA4 capture CD80 and CD86 from adjacent cellsSemantic proximity Read ↗

Precision immunotherapy for cholangiocarcinoma: Pioneering the use of human-derived anti-cMET single chain variable fragment in anti-cMET chimeric antigen receptor (CAR) NK cellsSemantic proximity Read ↗

Impact of the canine osteosarcoma tumor microenvironment on immune cell composition and gene expression profilesSemantic proximity Read ↗

A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignanciesSemantic proximity Read ↗

Direct comparison of canine and human immune responses using transcriptomic and functional analysesSemantic proximity Read ↗

Knocking out CD70 rescues CD70-specific nanoCAR T cells from antigen induced exhaustionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.